本帖最后由 老马 于 2012-1-13 21:20 编辑 % ^ v; O0 _# R3 u7 C: Q& P
3 Z! T, l7 p! P* |
爱必妥和阿瓦斯丁的比较$ H- B" u' q- H+ d8 `
" O/ q3 A/ W" ?. w; c3 l2 Mhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/7 R; K+ P B1 n, [7 b2 W
1 `+ ~+ W( B1 x- Z
; ?) l& a- y& A) W' Q0 Lhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/2 R( o: N8 {0 _9 _
==================================================
. q* C& X) S) A. A( ^, uOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
( t4 ?0 C! V) z* l; m* u$ xPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.8 l( K* @5 f. W' L
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.9 ~0 M+ \3 E1 `% y3 w: }' U( a
|
显身卡
) l8 \6 O; H' l+ ~% C. s" M! Y
